VC investors and medtech strategists alike at APACMed’s 2020 virtual conference agreed that the challenges presented by COVID-19 have given healthtech a higher profile and accelerated the arrival of health system workflow improvements.
The COVID-19 pandemic has impacted every avenue of the health care industry, from manufacturing, planning and output, to staffing and management, and how and where care is delivered.
Outside the immediate spotlight on the needs of COVID-19, medtech start-ups, entrepreneurs and founders have their own immediate concerns; they...
Create an account to read this article
Already a subscriber?
An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.
CEO Alexandre Chau told Medtech Insight that the Middle East and Africa presented the ideal mix of market potential, physician training opportunities, and regulatory readiness when the company was considering expansion markets beyond Europe and the US.
A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.
A surgeon at Ochsner Health in New Orleans was able to successfully remove a rare and dangerous tumor from a patient’s spine using cutting-edge technology that would have otherwise made the procedure too risky.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.
